<p>Patients with relapsed or recurrent small cell lung cancer or extra-pulmonary small cell cancers were enrolled on an investigator-initiated, single-arm, phase 2 trial (NCT02487095) combining an ATR inhibitor M6620 (VX-970, berzosertib) administered at 210 mg/m2 intravenously over 60 minutes on day 2 and day 5, and topotecan 1.25 mg/m2 intravenously over 30 minutes every 23 hours on days 1 through 5, with a support of pegfilgrastim 6mg subcutaneously on day 6 in 21-day cycles. Tumor samples were collected either just before starting the treatment or before starting treatment prior to be enrolled in the trial. Whole exome and RNA were sequenced to evaluate genomic and transcriptomic characteristics associated with the response to the combination treatment.</p>

Therapeutic Targeting of ATR Yields Durable Regressions in High    Replication Stress Tumors

14 variables across Demographics, Race and Ethnicity

Therapeutic Targeting of ATR Yields Durable Regressions in High Replication Stress Tumors

Demographics (2)

Race and Ethnicity (1)

Other (11)